| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 05/12/2011 | WO2011055881A1 Composition for preventing and treating influenza-virus-induced diseases |
| 05/12/2011 | WO2011055708A1 Isopropyl methyl phenol-containing liquid composition for oral cavity |
| 05/12/2011 | WO2011055398A1 A process for the production of immunoglobulines extracted from human plasma for therapeutic use, for the neutralization of the epstein-barr virus, and the medicine containing said immunoglobulins" |
| 05/12/2011 | WO2011054843A1 Bromodomain inhibitors for treating autoimmune and inflammatory diseases |
| 05/12/2011 | WO2011054834A1 Benzimidazole-imidazole derivatives |
| 05/12/2011 | WO2011054301A1 Use of danshensu, notoginsenoside r1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder |
| 05/12/2011 | WO2011054292A1 Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof |
| 05/12/2011 | WO2011054171A1 Tyrosine derivative histone deacetylases inhibitors and applications thereof |
| 05/12/2011 | WO2011008230A3 Rapamycin derivatives and ethers of n-propanolamines and uses related to infection |
| 05/12/2011 | WO2011005749A3 Topical antifungal composition |
| 05/12/2011 | WO2010151672A3 Amino acid derived ureas |
| 05/12/2011 | WO2010151640A3 Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease |
| 05/12/2011 | WO2010150982A9 Recombinant hemagglutinin protein having superior biocompatibility for an influenza virus vaccine, and method for preparing biodegradable plga microspheres containing same |
| 05/12/2011 | WO2010144908A3 Mammalian genes involved in tularemia and other infections |
| 05/12/2011 | WO2010130896A3 Method for admixing the lipopolysaccharide (lps) of gram-negative bacteria |
| 05/12/2011 | WO2010046663A3 Novel uses |
| 05/12/2011 | WO2010032266A9 Novel single unit carbapenem aminoglycoside formulations |
| 05/12/2011 | WO2010027501A8 Anti-lipid antibodies |
| 05/12/2011 | US20110112464 Meso-substituted porphyrins |
| 05/12/2011 | US20110112283 Rna interference mediating small rna molecules |
| 05/12/2011 | US20110112280 Use of rgm and its modulators |
| 05/12/2011 | US20110112195 Potent and Selective Inhibition by Aurinticarboxylic Acid |
| 05/12/2011 | US20110112193 Bis-aryl compounds for use as medicaments |
| 05/12/2011 | US20110112137 Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
| 05/12/2011 | US20110112114 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 05/12/2011 | US20110112100 Hepatitis C Virus Inhibitors |
| 05/12/2011 | US20110112096 Pyrimidine derivatives as kinase inhibitors |
| 05/12/2011 | US20110112090 Depsipeptides and Their Therapeutic Use |
| 05/12/2011 | US20110112082 Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 05/12/2011 | US20110112068 Human immunodeficiency virus protease inhibitors |
| 05/12/2011 | US20110112063 Pyrimidine derivatives as kinase inhibitors |
| 05/12/2011 | US20110112059 Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same |
| 05/12/2011 | US20110112058 Novel modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| 05/12/2011 | US20110112054 Organophosphorous Compounds for the Activation of Gamma/Delta T Cells |
| 05/12/2011 | US20110112046 Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
| 05/12/2011 | US20110112031 Optimized dengue virus entry inhibitory peptide (dn81) |
| 05/12/2011 | US20110111493 Compositions and Methods For Inhibiting Expression Of A Target Gene |
| 05/12/2011 | US20110111398 Nucleic acid probe-based diagnostic assays targeting ssra genes of prokaryotic and eukaryotic organisms |
| 05/12/2011 | US20110111073 Recovery of hydrophobic peptides from oils |
| 05/12/2011 | US20110111067 Oral herbal composition for the treatment of oral candidiasis |
| 05/12/2011 | US20110111064 Anti-Influenza Virus Agent, Anti-RS Virus Agent, and Anti-Immunodeficiency Virus Agent |
| 05/12/2011 | US20110111058 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
| 05/12/2011 | US20110111056 Peptide dicer substrate agents and methods for their specific inhibition of gene expression |
| 05/12/2011 | US20110111044 Nanoparticle compositions for nucleic acids delivery system |
| 05/12/2011 | US20110111042 Self-microemulsifying systems incorporated into liquid core microcapsules |
| 05/12/2011 | US20110111029 Composition for transdermal delivery of cationic active agents |
| 05/12/2011 | US20110111006 Conveniently implantable sustained release drug compositions |
| 05/12/2011 | US20110110982 Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| 05/12/2011 | US20110110980 Heterlogous prime-boost immunization regimen |
| 05/12/2011 | US20110110978 High titer recombinant influenza viruses with enhanced replication in vero cells |
| 05/12/2011 | US20110110977 Multiclade HIV Vaccines |
| 05/12/2011 | US20110110976 Rift valley fever virus-like particles and their use for immunization and as test system |
| 05/12/2011 | US20110110975 Inactivated virus compositions and methods of preparing such compositions |
| 05/12/2011 | US20110110973 Influenza B Vaccines |
| 05/12/2011 | US20110110972 Stimulation of an immune response by enantiomers of cationic lipids |
| 05/12/2011 | US20110110971 Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same |
| 05/12/2011 | US20110110970 Chimeric vaccines |
| 05/12/2011 | US20110110969 Peptide vaccines against group a streptococci |
| 05/12/2011 | US20110110968 Human optimized Bacillus anthracis protective antigen |
| 05/12/2011 | US20110110967 Gas57 mutant antigens and gas57 antibodies |
| 05/12/2011 | US20110110966 Novel immunogenic proteins of leptospira |
| 05/12/2011 | US20110110965 Compositions that induce t cell help |
| 05/12/2011 | US20110110961 Prolyl hydroxylase inhibitors |
| 05/12/2011 | US20110110954 Anthrax compositions and methods of use and production |
| 05/12/2011 | US20110110948 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
| 05/12/2011 | US20110110947 Viral chemokine-antigen fusion proteins |
| 05/12/2011 | US20110110939 Methods and compositions for the treatment and diagnosis of systemic anthrax infection |
| 05/12/2011 | US20110110930 Mitogen-Activated Protein Kinase Kinase Kinase 14 (MAP3K14) Polymorphisms As Indicators of Subject Outcome in Critically Ill Subjects |
| 05/12/2011 | US20110110928 Fc variants with altered binding to fcrn |
| 05/12/2011 | US20110110915 14189, a novel human kinase and uses thereof |
| 05/12/2011 | US20110110909 Human facilitating cells |
| 05/12/2011 | US20110110892 Vectors for delivering disease neutralizing agents |
| 05/12/2011 | US20110110891 Methods of Treating Hepatitis C Virus Infection |
| 05/12/2011 | US20110110890 Novel Inhibitors of Hepatitis C Virus Replication |
| 05/12/2011 | US20110110884 Immunotherapy for immune suppressed patients |
| 05/12/2011 | US20110110883 Methods of altering an immune response induced by cpg oligodeoxynucleotides |
| 05/12/2011 | US20110110861 Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells |
| 05/12/2011 | US20110110857 Mutant forms of chlamydia htra |
| 05/12/2011 | US20110110854 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules |
| 05/12/2011 | CA2816401A1 Generation of antigenic virus-like particles through protein-protein linkages |
| 05/12/2011 | CA2781322A1 Use of danshensu, notoginsenoside r1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder |
| 05/12/2011 | CA2780332A1 Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| 05/12/2011 | CA2780034A1 Benzimidazole-imidazole derivatives |
| 05/12/2011 | CA2779839A1 T-cell stimulating protein b and methods of use |
| 05/12/2011 | CA2779693A1 Copper salts of ion exchange materials for use in the treatment and prevention of infections |
| 05/12/2011 | CA2779515A1 Haemophilus parasuis polypeptides and methods of use |
| 05/12/2011 | CA2778907A1 Deuterated 5,6-dihydro-1h-pyridin-2-one compounds |
| 05/12/2011 | CA2778115A1 Imidazole derivatives as ido inhibitors |
| 05/12/2011 | CA2778081A1 Devices, methods, and composition for controlling infections |
| 05/12/2011 | CA2776563A1 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines |
| 05/11/2011 | EP2320233A1 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| 05/11/2011 | EP2319931A1 Extracellular matrix-binding proteins from staphylococcus aureus |
| 05/11/2011 | EP2319917A2 Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| 05/11/2011 | EP2319916A1 Cell capable of replicating novel hcv replicon, cell capable of replicating full-length hcv rna, and use of those cells |
| 05/11/2011 | EP2319870A2 Human antibodies that bind human IL-12 and methods for producing |
| 05/11/2011 | EP2319861A1 A method for identification, isolation and production of antigens to a specific pathogen |
| 05/11/2011 | EP2319856A1 Methods and compositions for treating hepatitis c virus |
| 05/11/2011 | EP2319541A1 Factor VII or VIIA-like conjugates |
| 05/11/2011 | EP2319532A1 Recombinant dengue virus containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 3, or 4 |
| 05/11/2011 | EP2319527A2 BAFF, inhibitors thereof and their use in the modulation of the B-cell response |